Patents Represented by Attorney, Agent or Law Firm Michael B. Farber, Esq.
  • Patent number: 6803183
    Abstract: In general, a method for removal of pyrogens from plasma or blood according to the present invention comprises: (1) passing the biological fluid through a resin comprising two components: (a) a first component comprising a polymeric support with a multiplicity of ligands comprising a C10-C24 alkylamino group, the ligands specifically binding endotoxin; and (b) a second component comprising a halogenated quinolone moiety immobilized on an amino-group-containing solid support by the formation of an amide linkage, the first component and the second component being present in the resin at a ratio of from about 20:80 (v/v) to about 80:20 (v/v); and (2) collecting the biological fluid from which pyrogens have been removed. Preferably, the alkylamino group is a stearylamino group, and the ligands are cross-linked and quaternized by reaction with a dibromoalkanol. Preferably, the polymeric support of the first component is agarose in particulate form.
    Type: Grant
    Filed: July 18, 2002
    Date of Patent: October 12, 2004
    Assignee: Clarigen, Inc.
    Inventors: Marie-Claude Amoureux, Edit Hegyi, Peter Grandics, Susan Szathmary
  • Patent number: 6767891
    Abstract: A number of peptides of from 28 to 44 amino acids, including therein a sequence of L-K-E-K-K (SEQ ID NO: 1), have a physiological activity that can be wound healing activity, immunostimulant activity, or growth factor activity. The peptides can be linear or circular, and, if linear, its amino terminus can be optionally acetylated. The invention also includes nucleic acids encoding these peptides, vectors incorporating these nucleic acid sequences, and host cells transfected with these vectors, as well as methods for producing these peptides by culturing these host cells and purifying the peptides. The invention further includes pharmaceutical compositions and methods for using these peptides.
    Type: Grant
    Filed: June 12, 2001
    Date of Patent: July 27, 2004
    Inventor: Chanda Zaveri
  • Patent number: 6745903
    Abstract: A new method is described to produce large volumes of low cost sterile, Water-for-Injection (WFI) grade water on-line, on-demand from potable water in order to meet the needs of dialysis therapies and other biological applications for sterile, injectable grade water. The source water is processed by a combination of membrane and column chromatographic methods including reverse osmosis, chemical sterilization, reduction of iodine sterilant to iodide, deionization, endotoxin-specific adsorption and polishing filtration in order to reduce contaminant levels below those specified by the US Pharmacopoeia.
    Type: Grant
    Filed: March 14, 2002
    Date of Patent: June 8, 2004
    Inventor: Peter Grandics
  • Patent number: 6350752
    Abstract: Disclosed herein are methods and associated compositions and medicaments directed generally to the control of cellular and neural activity and for selectively and controllably inducing the in vivo genetic expression of one or more naturally occurring genetically encoded molecules in mammals. More particularly, the present invention selectively activates or derepresses genes encoding for specific naturally occurring molecules such as proteins or neurotrophic factors and induces the endogenous production of such naturally occurring compounds through the administration of carbon monoxide dependent guanylyl cyclase modulating purine derivatives. The methods of the present invention may be used to affect a variety of cellular and neurological functions and activities and to therapeutically or prophylactically treat a wide variety of neurodegenerative, neurological, cellular, and physiological disorders.
    Type: Grant
    Filed: June 19, 1997
    Date of Patent: February 26, 2002
    Inventors: Alvin J. Glasky, Michel P. Rathbone
  • Patent number: 6338963
    Abstract: Disclosed herein are methods directed generally to the control of neural activity and for selectively and controllably inducing the in vivo genetic expression of one or more naturally occurring genetically encoded molecules in mammals. More particularly, the present invention selectively activates or derepresses genes encoding for specific naturally occurring molecules such as neurotrophic factors through the administration of carbon monoxide dependent guanylyl cyclase modulating purine derivatives. The methods of the present invention may be used to affect a variety of cellular and neurological activities and to therapeutically or prophylactically treat a wide variety of neurodegenerative, neurological, and cellular disorders.
    Type: Grant
    Filed: October 19, 1999
    Date of Patent: January 15, 2002
    Assignee: NeoTherapeutics, Inc.
    Inventors: Alvin J. Glasky, Michael P. Rathbone